Fund Description
The investment seeks performance results that correspond to the price and yield performance, before fees and expenses, of the Dow Jones U.S. Thematic Market Neutral Anti-Beta Index. The fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in common stock, including the short positions, in the Target Anti-Beta Index. The Target Anti-Beta Index is a market neutral index that is dollar-neutral. As such, it identifies long and short securities positions of approximately equal dollar amounts. In choosing to track a market neutral index, the fund seeks to limit the effects of general market movements on the fund.
Fund Snapshot Updated 05.23.2013
| Previous Close | $21.21 | Expense Ratio | 1.92% |
| YTD Return | 2.0% | Avg. 30-Day Volume | 1,630 |
| 1-Year Return | 9.6% | Market Cap | Loading... |
| Bid | $21.01 | Shares Outstanding | 650,000 |
| Ask | $21.47 | Dividends | $0.00 |
| Top 10 Holdings | |
|---|---|
| Actavis Inc (ACT) | 0.60% |
| Bristol Myers Squibb Co (BMY) | 0.58% |
| Vertex Pharmaceuticals Inc (VRTX) | 0.58% |
| Old Dominion Fght Lines Inc (ODFL) | 0.55% |
| Mckesson Corp (MCK) | 0.55% |
| Dril-Quip Inc (DRQ) | 0.54% |
| Quest Diagnostics Inc (DGX) | 0.54% |
| Precision Castparts Corp (PCP) | 0.54% |
| Gilead Sciences Inc (GILD) | 0.54% |
| Werner Enterprises Inc (WERN) | 0.54% |
| % of Total Holdings | 5.60% |
